Drug Search Results
More Filters [+]

XP-21279

Alternative Names: xp-21279, xp21279, xp 21279
Latest Update: 2021-05-05
Latest Update Note: Clinical Trial Update

Product Description

For Parkinson's Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01171313)

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: XenoPort
Company Location: REDWOOD CITY CA 94063
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for XP-21279

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

XP-C-069

P2

Completed

Parkinson's Disease

2011-10-01

31%

XP-C-058

P2

Completed

Parkinson's Disease

2010-01-01

31%

Recent News Events

Date

Type

Title